AU2016351454A1 - Nutritional compositions containing butyrate and uses thereof - Google Patents

Nutritional compositions containing butyrate and uses thereof Download PDF

Info

Publication number
AU2016351454A1
AU2016351454A1 AU2016351454A AU2016351454A AU2016351454A1 AU 2016351454 A1 AU2016351454 A1 AU 2016351454A1 AU 2016351454 A AU2016351454 A AU 2016351454A AU 2016351454 A AU2016351454 A AU 2016351454A AU 2016351454 A1 AU2016351454 A1 AU 2016351454A1
Authority
AU
Australia
Prior art keywords
nutritional composition
butyrate
composition
protein
dietary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016351454A
Inventor
Juan M. Gonzalez
Teartse Tim Lambers
Eric A.F. Van Tol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MJN US Holdings LLC
Original Assignee
MJN US Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/936,014 external-priority patent/US20170127693A1/en
Priority claimed from US14/959,107 external-priority patent/US10034937B2/en
Priority claimed from US15/011,797 external-priority patent/US20170215464A1/en
Application filed by MJN US Holdings LLC filed Critical MJN US Holdings LLC
Publication of AU2016351454A1 publication Critical patent/AU2016351454A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus

Abstract

Provided are nutritional compositions containing dietary butyrate. The nutritional compositions may exhibit additive or synergistic beneticial health effects when consumed. Further provided are methods for improving the shelf-stability and/or organoleptic properties of nutritional compositions including dietary butyrate.

Description

DESCRIPTION
NUTRITIONAL COMPOSITIONS CONTAINING BUTYRATE AND USES THEREOF
TECHNICAL FIELD [0001] The present disclosure reiates generaiiy to nutritionai compositions comprising dietary butyrate that are suitable for administration to pediatric subjects. Additionally, the disclosure reiates to methods for improving the shelf-stability of nutritionai compositions including dietary butyrate, and methods for improving the organoleptic properties of nutritional compositions including dietary butyrate. The disclosed nutritional compositions may provide additive and or/synergistic beneficial health effects.
BACKGROUND ART [0002] Administration of nutritionai compositions or other compositions including butyrate or butyrate derivatives often suffer from difficuities regarding the availability of butyrate upon administration. For example, certain butyrate derivatives undergo degradation or oxidation, which ultimate affect the bioavailabiiity of the butyrate derivative upon ingestion. As such, compositions including butyrate derivatives may not provide nutritional efficacy upon ingestion given the degradation of the butyrate derivative.
[0003] Additionally, nutritional compositions including butyrate may suffer from poor paiatabiiity. The unpleasant taste and odor of compositions including butyrate can make the oral administration of certain nutritional compositions including butyrate difficult, especially in the pediatric population. For example, certain butyric acid derivatives at room temperature are present as a dense liquid having an unpleasant intense odor.
[0004] Accordingly, it would be beneficia! to provide a nutritional composition that includes dietary butyrate having improved shelf-stability and organoleptic properties. Additionally, it is beneficial to provide methods of producing a nutritional composition including dietary butyrate having improved sheif stability and organoleptic properties.
DISCLOSURE OF THE INVENTION [0005] Briefly, the present disclosure is directed, in an embodiment, to a nutritionai composition that includes dietary butyrate. In some embodiments, the dietary butyrate may be encapsulated. In some embodiments, the dietary butyrate may be provided by an enriched lipid fraction derived from milk.
WO 2017/083067
PCT/US2016/057641 [0006] in certain embodiments, the nutritiona! composition includes dietary butyrate that has improved organoleptic properties. In some embodiments, the nutritional composition including dietary butyrate has improved shelf-stability.
[0007] Additionally, the disciosure is directed to a methods for improving the sheif stability and/or organoleptic properties of a nutritional composition including dietary butyrate.
[0008] it is to be understood that both the foregoing general description and the foliowing detailed description present embodiments of the disciosure and are intended to provide an overview or framework for understanding the nature and character of the disciosure as it is claimed. The description serves to explain the principies and operations of the claimed subject matter. Other and further features and advantages of the present disciosure wiil be readily apparent to those skilled in the art upon a reading of the following disciosure.
BEST MODE FOR CARRYING OUT THE INVENTION [0009] Reference now will be made in detail to the embodiments of the present disclosure, one or more examples of which are set forth herein below. Each example is provided by way of explanation of the nutritional composition of the present disclosure and is not a limitation. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made to the teachings of the present disclosure without departing from the scope of the disclosure. For instance, features illustrated or described as part of one embodiment, can be used with another embodiment to yield a still further embodiment.
[0010] Thus, it is intended that the present disclosure covers such modifications and variations as come within the scope of the appended claims and their equivalents. Other objects, features and aspects of the present disclosure are disclosed in or are apparent from the following detailed description. It is to be understood by one of ordinary skili in the art that the present discussion is a description of exemplary embodiments only and is not intended as limiting the broader aspects of the present disclosure.
[0011] The present disclosure relates generally to nutritional compositions comprising dietary butyrate. Additionaily, the disciosure relates to methods for improving the sheif stability and/or organoleptic properties of nutritional compositions including butyrate. [0012] “ Nutritiona! composition means a substance or formulation that satisfies at least a portion of a subject’s nutrient requirements. The terms “nutritional(s), “nutritional formula(s)”, “enteral nutritional(s), and “nutritional suppiement(s)” are used as nonWO 2017/083067
PCT/US2016/057641 limiting examples of nutritional composition(s) throughout the present disclosure.
Moreover, “nutritional composition(s) may refer to liquids, powders, gels, pastes, solids, concentrates, suspensions, or ready-to-use forms of enteral formulas, orai formulas, formulas for infants, formulas for pediatric subjects, formulas for children, growing-up milks and/or formulas for adults.
[0013] “ Pediatric subject means a human less than 13 years of age. In some embodiments, a pediatric subject refers to a human subject that is between birth and 8 years old. In other embodiments, a pediatric subject refers to a human subject between 1 and 6 years of age. In still further embodiments, a pediatric subject refers to a human subject between 6 and 12 years of age. The term “pediatric subject may refer to infants (preterm or fuilterm) and/or children, as described below.
[0014] “ Infant means a human subject ranging in age from birth to not more than one year and includes infants from 0 to 12 months corrected age. The phrase “corrected age” means an infant’s chronologica! age minus the amount of time that the infant was bom premature. Therefore, the corrected age is the age of the infant if it had been carried to full term. The term infant includes low birth weight infants, very low birth weight infants, and preterm infants. “Preterm means an infant born before the end of the 37th week of gestation. “Full term means an infant born after the end of the 37th week of gestation.
[0015] “ Child” means a subject ranging in age from 12 months to about 13 years. In some embodiments, a child is a subject between the ages of 1 and 12 years old. in other embodiments, the terms children” or “child” refer to subjects that are between one and about six years old, or between about seven and about 12 years old. In other embodiments, the terms “children” or “child refer to any range of ages between 12 months and about 13 years.
[0016] “ Infant formula means a composition that satisfies at least a portion of the nutrient requirements of an infant. In the United States, the content of an infant formula is dictated by the federal regulations set forth at 21 C.F.R. Sections 100, 106, and 107. [0017] “ Fractionation procedure includes any process in which a certain quantity of a mixture is divided up into a number of smaller quantities known as fractions. The fractions may be different in composition from both the mixture and other fractions. Examples of fractionation procedures include but are not limited to meit fractionation, solvent fractionation, supercriticai fluid fractionation and/or combinations thereof. [0018] “ Milk fat globule membrane” includes components found in the milk fat globule membrane including but not limited to milk fat globule membrane proteins such as
WO 2017/083067
PCT/US2016/057641
Mucin 1, Butyrophiiin, Adipophiiin, CD36, CD 14, Lactadherin (PAS6/7), Xanthine oxidase and Fatty Acid binding proteins etc, [0019] The term growing-up milk refers to a broad category of nutritional compositions intended to be used as a part of a diverse diet in order to support the normal growth and development of a child between the ages of about 1 and about 6 years of age.
[0020] “ Milk” means a component that has been drawn or extracted from the mammary giand of a mammal. In some embodiments, the nutritional composition comprises components of milk that are derived from domesticated unguiates, ruminants or other mammals or any combination thereof.
[0021] “Nutritionaily complete means a composition that may be used as the sole source of nutrition, which would supply essentially all of the required daily amounts of vitamins, minerals, and/or trace elements in combination with proteins, carbohydrates, and lipids, indeed, nutritionally complete” describes a nutritional composition that provides adequate amounts of carbohydrates, lipids, essential fatty acids, proteins, essential amino acids, conditionaily essential amino acids, vitamins, minerals and energy required to support normal growth and development of a subject.
[0022] A nutritional composition that is nutritionally complete” for a fuil term infant will, by definition, provide qualitatively and quantitatively adequate amounts of ail carbohydrates, lipids, essential fatty acids, proteins, essential amino acids, conditionaliy essential amino acids, vitamins, minerals, and energy required for growth of the fuil term infant.
[0023] A nutritional composition that is “nutritionaily complete for a child will, by definition, provide qualitatively and quantitatively adequate amounts of ail carbohydrates, lipids, essentia! fatty acids, proteins, essential amino acids, conditionally essential amino acids, vitamins, minerals, and energy required for growth of a child. [0024] “Dietary butyrate” as used herein refers to butyrate and butyrate derivatives. Non-limiting examples of dietary butyrate include butyric acid, butyrate salts, and glycerol esters of butyric acid.
[0025] The term “degree of hydrolysis” refers to the extent to which peptide bonds are broken by a hydrolysis method. The degree of protein hydrolysis for purposes of characterizing the hydrolyzed protein component of the nutritional composition is easily determined by one of ordinary skill in the formulation arts by quantifying the amino nitrogen to totai nitrogen ratio (AN/TN) of the protein component of the selected formulation. The amino nitrogen component is quantified by USP titration
WO 2017/083067
PCT/US2016/057641 methods for determining amino nitrogen content, while the totai nitrogen component is determined by the Kjeidahi method, ail of which are well known methods to one of ordinary skill in the analytical chemistry art.
[0026] When a peptide bond in a protein is broken by enzymatic hydrolysis, one amino group is released for each peptide bond broken, causing an increase in amino nitrogen. It should be noted that even non-hydrolyzed protein would contain some exposed amino groups. Hydrolyzed proteins will also have a different molecular weight distribution than the non-hydrolyzed proteins from which they were formed. The functional and nutritional properties of hydrolyzed proteins can be affected by the different size peptides. A molecular weight profile is usually given by listing the percent by weight of particular ranges of molecular weight (in Daltons) fractions (e.g., 2,000 to 5,000 Daltons, greater than 5,000 Daltons).
[0027] The term “molar mass distribution” when used in reference to a hydrolyzed protein or protein hydrolysate pertains to the molar mass of each peptide present in the protein hydrolysate. For example, a protein hydrolysate having a molar mass distribution of greater than 500 Daltons means that each peptide included in the protein hydrolysate has a molar mass of at least 500 Daltons. To produce a protein hydrolysate having a molar mass distribution of greater than 500 Daltons, a protein hydrolysate may be subjected to certain filtering procedures or any other procedure known in the art for removing peptides, amino acids, and/or other proteinaceous material having a molar mass of less than 500 Daltons. For the purposes of this disclosure, any method known in the art may be used to produce the protein hydrolysate having a molar mass distribution of greater than 500 Dalton.
[0028] The term “protein equivalent” or “protein equivalent source includes any protein source, such as soy, egg, whey, or casein, as wel! as non-protein sources, such as peptides or amino acids. Further, the protein equivalent source can be any used in the art, e.g., nonfat milk, whey protein, casein, soy protein, hydrolyzed protein, amino acids, and the like. Bovine milk protein sources useful in practicing the present disclosure include, but are not limited to, milk protein powders, milk protein concentrates, milk protein isolates, nonfat miik solids, nonfat milk, nonfat dry milk, whey protein, whey protein isolates, whey protein concentrates, sweet whey, acid whey, casein, acid casein, caseinate (e.g. sodium caseinate, sodium calcium caseinate, calcium caseinate), soy bean proteins, and any combinations thereof. The protein equivalent source can, in some embodiments comprise hydrolyzed protein, including
WO 2017/083067
PCT/US2016/057641 partially hydrolyzed protein and extensively hydroiyzed protein. The protein equivalent source may, in some embodiments, include intact protein.
[0029] The term protein equivalent source also encompasses free amino acids. In some embodiments, the amino acids may comprise, but are not limited to, histidine, isoleucine, ieucine, lysine, methionine, cysteine, phenylalanine, tyrosine, threonine, tryptophan, valine, alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, proline, serine, carnitine, taurine and mixtures thereof. In some embodiments, the amino acids may be branched chain amino acids. In certain other embodiments, small amino acid peptides may be included as the protein component of the nutritional composition. Such small amino acid peptides may be naturally occurring or synthesized.
[0030] The term partially hydrolyzed means having a degree of hydrolysis which is greater than 0% but less than about 50%.
[0031] The term extensively hydrolyzed” means having a degree of hydrolysis which is greater than or equal to about 50%. Accordingly, extensively hydrolyzed casein fraction (s) means casein having a degree of hydrolysis which is greater than or equal to about 50%. In some embodiments, extensively hydroiyzed may include a degree of hydrolysis of greater than about 80%. In further embodiments, extensively hydrolyzed may include a degree of hydrolysis of greater than about 90%.
[0032] The term protein-free means containing no measurable amount of intact protein, as measured by standard protein detection methods such as sodium dodecyl (lauryl) sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) or size exclusion chromatography. In some embodiments, the nutritional composition is substantially free of protein, wherein substantially free” is defined hereinbelow.
[0033] The nutritional composition of the present disclosure may be substantially free of any optional or selected ingredients described herein, provided that the remaining nutritional composition still contains all of the required ingredients or features described herein. In this context, and unless otherwise specified, the term substantially free” means that the selected composition may contain less than a functional amount of the optional ingredient, typicaliy less than 0.1% by weight, and also, including zero percent by weight of such optional or selected ingredient.
[0034] Ail percentages, parts and ratios as used herein are by weight of the totai composition, unless otherwise specified.
WO 2017/083067
PCT/US2016/057641 [0035] All references to singular characteristics or limitations of the present disclosure shall include the corresponding plural characteristic or limitation, and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.
[0036] Ail combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.
[0037] The methods and compositions of the present disclosure, including components thereof, can comprise, consist of, or consist essentially of the essential elements and limitations of the embodiments described herein, as well as any additional or optional ingredients, components or limitations described herein or otherwise useful in nutritional compositions.
[0038] As used herein, the term “about” should be construed to refer to both of the numbers specified as the endpointfs} of any range. Any reference to a range should be considered as providing support for any subset within that range.
[0039] The present disclosure is directed to nutritional compositions including dietary butyrate. The nutritional compositions may further include a carbohydrate source, a protein source, and a fat source.
[0040] In some embodiments, the nutritional composition includes a source of dietary butyrate that is present in an amount of from about 0.2 g/100 g fatty acids to about 1.8 g/100 g fatty acids where the fat source constitutes from about 4 g fat/100 Kcal to about 6 g fat/100 Kcal.
[0041] In some embodiments the dietary butyrate is provided by one or more of the following: butyric acid; butyrate salts, including sodium butyrate, potassium butyrate, calcium butyrate, and/or magnesium butyrate; glycerol esters of butyric acid; and/or corresponding mixtures and corresponding salts of pharmaceutically acceptable bases or acids, pure diastereoisomeric forms and enantiomeric forms or mixtures thereof.
[0042] In some embodiments, the dietary butyrate is supplied by any suitable source known in the art. Non-limiting sources of dietary butyrate includes animal source fats and derived products, such as but not limited to miik, milk fat, butter, buttermilk, butter serum, cream,; microbial fermentation derived products, such as but not limited to yogurt, fermented buttermilk, cheese, beverages; and plant source derived seed oil products, such as pineapple, and apricot. In some embodiments, the dietary butyrate is synthetically produced. In embodiments where the dietary butyrate is synthetically
WO 2017/083067
PCT/US2016/057641 produced, the chemical structure of the dietary butyrate can be formed and modified as necessary. Further, the dietary butyrate produced syntheticaily can be purified by any means known in the art to produce a purified dietary butyrate additive that can be incorporated into the nutritional compositions disclosed herein.
[00431 In some embodiments, the dietary butyrate may be provided in an encapsulated form. In certain embodiments, the encapsulation of the dietary butyrate may provide for longer shelf-stability and may provide for improved organoleptic properties of the nutritional composition. For example, in some embodiments, the dietary butyrate may be coated or encapsulated by the use of, or combination of, fat derived materials, such as mono- and di-glycerides, sugar and acid esters of glycerides, phospholipids; plant, animal and microbial derived proteins and hydrocolloids, such as starches, maltodextrins, gelatin, pectins, glucans, caseins, soy proteins, whey proteins.
[00441 in certain embodiments, the dietary butyrate comprises glycerol esters of butyric acid and/or alkyl esters of butyric acid. Glycerol esters of butyric acid may offer minimal complexity when formulated and processed in the nutritional composition. Additionally, giycerol esters of butyric acid may improve the shelf life of the nutritional composition including dietary butyrate and may further have a low impact on the sensory attributes of the finished product.
[00451 In some embodiments, dietary butyrate may comprise butyric acid amide derivatives using other amino acids, for example, tyrosine and/or histidine. In some embodiments, any suitable amino acid known in the art may be utilized in preparing the butyric acid amide derivative used as a source of dietary butyrate. Without being bound by any particular theory, it is believed that dietary butyrate comprised of butyric acid amide derivatives may resist the action of gastric acids and the processing conditions encountered in nutritiona! composition, such as infant formula, manufacturing. Accordingly, in embodiments where the dietary butyrate is provided by one or more butyric acid amide derivatives the resulting nutritional composition includes a stable dietary butyrate formulation with improved organoleptic properties. [0046] The dietary butyrate may in some embodiments comprise butyrate salts, for example, sodium butyrate, potassium butyrate, calcium butyrate, magnesium butyrate, and combinations thereof. In some embodiments, the use of selected dietary butyrate salts may improve intestinal health when provided to target subjects.
In certain embodiments, dietary butyrate comprises a suitable butyrate salt that has been coated with one or more fats or iipids. In certain embodiments wherein the
WO 2017/083067
PCT/US2016/057641 dietary butyrate comprises a fat coated butyrate sait, the nutritional composition may be a dry-powdered composition into which the dietary butyrate is incorporated.
[00471 In embodiments, the dietary butyrate may comprise any of the butyrate compounds disclosed herein that are formulated to be in complex form with chitosan or one or more cyclodextrins. For example, cyclodextrins are cyclic oiigosaccharides composed of six (a-cyclodextrin), seven (β-cyciodextrin), or eight (gammacyclodextrin) units of a-l,4-glucopyranose. Cyciodextrins are further characterized by a hydrophilic exterior surface and a hydrophobic core. Without being bound by any particuiar theory, the aiiphatic butyrate chain would form a complex with the cyclodextrin core, thus increasing its molecular weight and, thus, reducing the volatility of the butyrate compound. Accordingly, the bioavailability of dietary butyrate may be improved when the dietary butyrate includes butyrate compounds in complex form with one or more cyclodextrins. Further, cyclodextrins are bulky hydrophobic molecules that are resistant to stomach acid as well as gastrointestinal enzymes, thus administration of the butyrate-cyclodextrin complex as described herein would promote absorption of the dietary butyrate in the small intestine.
[00481 The dietary butyrate can be provided from an enriched lipid fraction derived from miik in certain embodiments. For example, bovine miik fat has a butyric acid content that may be 20 times higher than the butyric acid content present in human milk fat. Furthermore, among the short chain fatty acids (“SCFAs) present in human milk, i.e. fatty acids having a carbon chain length from 4 to 12, butyric acid (C4) is one of the most predominant in bovine miik. As such, bovine milk fat and/or enriched fractions of bovine milk fat may be included in a nutritional composition to provide dietary butyrate.
[0049] In embodiments where the dietary butyrate is provided by an enriched lipid fraction derived from miik the enriched lipid fraction derived from milk may be produced by any number of fractionation techniques. These techniques include but are not limited to melting point fractionation, organic solvent fractionation, super critica! fluid fractionation, and any variants and combinations thereof.
[0050] Furthermore, mixtures that may be subjected to the fractionation procedures to produce the enriched lipid fraction include, but are not limited to, bovine whole milk, bovine cream, caprine milk, ovine miik, yak miik and/or mixtures thereof. In a preferred embodiment the milk mixture used to create the enriched iipid fraction is bovine milk. [0051] In addition to providing dietary butyrate, the enriched lipid fraction may comprise an one of the following ingredients: saturated fatty acids; trans-fatty acids;
WO 2017/083067
PCT/US2016/057641 branched-chain fatty acids (“BCFAs), including odd-branched chain fatty acids (‘OBCFAs); conjugated iinoieic acid (“CLA”); monounsaturated fatty acids;
polyunsaturated fatty acids; cholesteroi; phospholipids; and miik fat globule membrane, including miik fat globuie membrane protein.
[00521 in some embodiments the enriched lipid fraction includes, per 100 Kcal, one or more of the following:
from about 0.1 g to 8.0 g of saturated fatty acids; from about 0.2 g to 7.0 g trans-fatty acids; from about 0.003 g to about 6.1 g branched-chain fatty acids; from about 0.026 g to about 2.5 g conjugated iinoieic acid; from about 0.8 g to about 2.5 g monounsaturated fatty acids; from about 2.3 g to about 4.4 g polyunsaturated fatty acids; from about 100 mg to about 400 mg of cholesterol; from about 50 mg to about 400 mg of phospholipids; and/or from about 10 mg to about 500 mg of miik fat globuie membrane.
Example 1 [00531 Illustrated below are two lipid profiles of fractionated milk fat produced by super critical carbon extraction fractionation procedure and by melt-fractionation.
g/100 g fatty acids
SCCO2* MeltFrac**
C 4:0 5.95 4.67
C 6:0 3.28 2.89
C 8:0 1.91 1.76
C 10:0 3.90 3.83
C 12:0 4.14 4.81
C 14:0 12.18 10.87
C 14:1 1.00 1.32
C 15:0 1.03 0.94
C 16:0 29.55 22.27
C 16:1 1.37 2.21
C 17:0 0.50 0.42
C 18:0 8.16 6.08
C 18:1, cis, co9 16.47 25.27
WO 2017/083067
PCT/US2016/057641
c 18:1, trans, ω9 1.64 1.88
c 18:2, ω 6 2.16 1.90
c 18:3, ω3, ω 0.40 0.59
c 20:0 0.06 0.06
c 20:1, ω 9 0.08 0.17
Saturated 70.66 58.59
Unsaturated 23.13 33.34
* SCCO2 = super-critical carbon dioxide fraction (super olein).
** MeltFrac = melt crystallization fraction separated at 10°C.
[0054] In certain embodiments, dietary butyrate is incorporated into a nutritional composition that is an infant formula. Certain butyrate compounds, such as acid salts and alkyl esters of butyric acid, exhibit an odor that makes consuming the nutritional composition in which they are incorporated an unpleasant experience. Furthermore, the pediatric and infant population will not readily consume products having an unpleasant odor, taste, and/or mouthfeel. Accordingly, there exists a need for a nutritional composition formulated for administration to a pediatric subject or an infant that includes dietary butyrate yet does not have diminished organoleptic properties. The incorporation of certain dietary butyrate compounds disclosed herein, i.e. glycerol esters of butyric acid, butyrate enriched milk fat fractions, and amide derivatives of amino acids, into pediatric and infant nutritional compositions will provide a source of dietary butyrate while still providing a pleasant sensory experience.
[0055] The nutritional composition(s) of the present disclosure may also comprise a carbohydrate source. Carbohydrate sources can be any used in the art, e.g., lactose, glucose, fructose, corn syrup solids, maltodextrins, sucrose, starch, rice syrup solids, and the like. The amount of carbohydrate in the nutritional composition typically can vary from between about 5 g and about 25 g/100 Kcal. In some embodiments, the amount of carbohydrate is between about 6 g and about 22 g/ 100 Kcal. In other embodiments, the amount of carbohydrate is between about 12 g and about 14 g/100 Kcal. In some embodiments, corn syrup solids are preferred. Moreover, hydrolyzed, partially hydrolyzed, and/or extensively hydrolyzed carbohydrates may be
WO 2017/083067
PCT/US2016/057641 desirable for inclusion in the nutritional composition due to their easy digestibility. Specifically, hydrolyzed carbohydrates are less likely to contain allergenic epitopes. [0056] Non-limiting examples of carbohydrate materials suitable for use herein include hydrolyzed or intact, naturally or chemically modified, starches sourced from corn, tapioca, rice or potato, in waxy or non-waxy forms. Non-limiting examples of suitable carbohydrates include various hydrolyzed starches characterized as hydrolyzed cornstarch, maltodextrin, maltose, corn syrup, dextrose, corn syrup solids, glucose, and various other glucose polymers and combinations thereof. Non-limiting examples of other suitable carbohydrates include those often referred to as sucrose, lactose, fructose, high fructose corn syrup, indigestible oligosaccharides such as fructooligosaccharides and combinations thereof.
[0057] The nutritional composition(s) of the disclosure may also comprise a protein source. The protein source can be any used in the art, e.g., nonfat milk, whey protein, casein, soy protein, hydrolyzed protein, amino acids, and the like. Bovine milk protein sources useful in practicing the present disclosure include, but are not limited to, milk protein powders, milk protein concentrates, milk protein isolates, nonfat milk solids, nonfat milk, nonfat dry milk, whey protein, whey protein isolates, whey protein concentrates, sweet whey, acid whey, casein, acid casein, caseinate (e.g. sodium caseinate, sodium calcium caseinate, calcium caseinate) and any combinations thereof.
[0058] In one embodiment, the proteins of the nutritional composition are provided as intact proteins. In other embodiments, the proteins are provided as a combination of both intact proteins and partially hydrolyzed proteins, with a degree of hydrolysis of between about 4% and 10%. in certain other embodiments, the proteins are more completely hydrolyzed. In still other embodiments, the protein source comprises amino acids. In yet another embodiment, the protein source may be supplemented with giutamine-containing peptides.
[0059] In some embodiments, the nutritionai composition may include a protein equivalent source, wherein at least 1% of the protein equivalent source comprises extensively hydrolyzed casein and up to 99% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, amino acids, or combinations thereof. In embodiments, 1% to 80% of the protein equivalent source comprises extensively hydrolyzed casein and 20% to 99% of the protein equivalent source comprises intact protein, partially hydrolyzed protein, amino acids, or combinations thereof. In still other embodiments, from 40% to 100% of the protein
WO 2017/083067
PCT/US2016/057641 equivalent source comprises extensively hydroiyzed casein and from 0 to 60% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, amino acids, or combinations thereof. In yet other embodiments, from 40% to 70% of the protein equivalent source comprises extensively hydrolyzed casein and from 30% to 60% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, amino acids, or combinations thereof.
[0060] In some embodiments, extensively hydrolyzed casein may be present in the nutritional composition in an amount from about 0.2 g/100 kcal to about 5.6 g/100 kcai In other embodiments extensively hydroiyzed casein may be present in the nutritional composition in an amount from about 1 g/100 kcal to about 4 g/100 kcal. In still other embodiments, extensively hydroiyzed casein may be present in the nutritional composition in an amount from about 2 g/100 kcal to about 3 g/100 kcal.
[0061] The protein equivalent source disclosed herein may be formulated with other ingredients in the nutritional composition to provide appropriate nutrient levels for the target subject. In some embodiments, the protein equivalent source is included in a nutritionally complete formula that is suitable to support normal growth.
[0062] In some embodiments, the protein equivalent source comprises a hydrolyzed protein, such as casein, which includes partially hydrolyzed protein and extensively hydrolyzed protein (i.e., the extensively hydroiyzed casein). In some embodiments, the extensively hydrolyzed casein comprises an extensively hydroiyzed casein and/or fractions thereof including peptides having a molar mass distribution of greater than 500 Daltons. In some embodiments, the extensively hydrolyzed casein comprises peptides having a molar mass distribution in the range of from about 500 Daltons to about 1,500 Daltons. Still, in some embodiments the extensively hydrolyzed casein may comprise peptides having a molar mass distribution range of from about 500 Daltons to about 2,000 Daltons.
[0063] In some embodiments the protein equivalent source comprises partially hydrolyzed protein having a degree of hydrolysis of less than 40%. In still other embodiments, the protein equivalent source may comprise partially hydrolyzed protein having a degree of hydrolysis of less than 25%, or less than 15%.
[0064] In a particular embodiment, the nutritional composition is protein-free and contains free amino acids as a protein equivalent source. In this embodiment, the amino acids may comprise, but are not limited to, histidine, isoleucine, leucine, lysine, methionine, cysteine, phenylalanine, tyrosine, threonine, tryptophan, vaiine, alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine, proline, serine,
WO 2017/083067
PCT/US2016/057641 carnitine, taurine and mixtures thereof. In some embodiments, the amino acids may be branched chain amino acids. In other embodiments, small amino acid peptides may be included as the protein component of the nutritional composition. Such small amino acid peptides may be naturally occurring or synthesized. The amount of free amino acids in the nutritional composition may vary from about 1 to about 5 g/100 kcal. In an embodiment, 100% of the free amino acids have a molecular weight of less than 500 Daltons. In this embodiment, the nutritional composition may be hypoallergenic.
[0065] In an embodiment, where the protein equivalent source comprises intact proteins, the intact proteins comprise from about 40% to about 85% whey protein and from about 15% to about 60% casein.
[0066] In a particular embodiment of the nutritional composition, the whey:casein ratio of the protein source is similar to that found in human breast milk. In an embodiment, the protein source comprises from about 40% to about 80% whey protein and from about 20% to about 60% casein.
[0067] In some embodiments, the nutritional composition comprises between about 1 g and about 7 g of a protein source per 100 Kcal. In other embodiments, the nutritional composition comprises between about 3.5 g and about 4.5 g of protein per 100 Kcal. [0068] In some embodiments, the nutritional composition described herein comprises a fat source. The enriched lipid fraction described herein may be the sole fat source or may be used in combination with any other suitable fat or lipid source for the nutritional composition as known in the art. Appropriate fat sources include, but are not limited to, animal sources, e.g., milk fat, butter, butter fat, egg yolk lipid; marine sources, such as fish oils, marine oils, single cell oils; vegetable and plant oils, such as corn oil, canola oil, sunflower oil, soybean oil, palm olein oil, coconut oil, high oleic sunflower oil, evening primrose oil, rapeseed oil, olive oil, flaxseed (linseed) oil, cottonseed oil, high oleic safflower oil, palm stearin, palm kernel oil, wheat germ oil; medium chain triglyceride oils and emulsions and esters of fatty acids; and any combinations thereof. [0069] In some embodiments the nutritional composition may also include a source of long chain polyunsaturated fatty acids (LCPUFAs). In one embodiment the amount of LCPUFA in the nutritional composition is advantageously at least about 5 mg/100 Kcal, and may vary from about 5 mg/100 Kcal to about 100 mg/100 Kcai, more preferably from about 10 mg/100 Kcal to about 50 mg/100 Kcal. Nomiimiting examples of LCPUFAs include, but are not limited to, docosahexaenoic acid (DHA), arachidonic acid (ARA), linoleic (18:2 n-6), γ-linoienic (18:3 n-6), dihomo- γ-linoienic ¢20:3 n-6) acids
WO 2017/083067
PCT/US2016/057641 in the n-6 pathway, a-linolenic ¢18:3 n-3), stearidonic ¢18:4 n-3), eicosatetraenoic (20:4 n-3), eicosapentaenoic (20:5 n-3), and docosapentaenoic ¢22:6 n-3).
[0070] in some embodiments, the LCPUFA included in the nutritional composition may comprise DHA. In one embodiment the amount of DHA in the nutritional composition is advantageously at least about 1 7 mg/100 Kcal, and may vary from about 5 mg/100 Kcal to about 75 mg/100 Kcal, more preferably from about 10 mg/100 Kcal to about 50 mg/100 Kcal.
[0071] In another embodiment, especially if the nutritional composition is an infant formula, the nutritional composition is supplemented with both DHA and ARA. In this embodiment, the weight ratio of ARA:DHA may be between about 1:3 and about 9:1. In a particular embodiment, the ratio of ARA:DHA is from about 1:2 to about 4:1.
[0072] The DHA and ARA can be in natural form, provided that the remainder of the LCPUFA source does not result in any substantial deleterious effect on the infant. Alternatively, the DHA and ARA can be used in refined form.
[0073] The disclosed nutritional composition described herein can, in some embodiments, also comprise a source of B-glucan. Glucans are polysaccharides, specifically polymers of glucose, which are naturally occurring and may be found in cell walls of bacteria, yeast, fungi, and plants. Beta glucans (β-glucans) are themselves a diverse subset of glucose polymers, which are made up of chains of glucose monomers linked together via beta-type glycosidic bonds to form complex carbohydrates.
[0074] p-1,3-glucans are carbohydrate polymers purified from, for example, yeast, mushroom, bacteria, algae, or cereals. (Stone BA, Clarke AE. Chemistry and Biology of (l-3)-Beta-Glucans. London:Portland Press Ltd; 1993.) The chemical structure of β-l,3giucan depends on the source of the β-l ,3-glucan. Moreover, various physiochemical parameters, such as solubility, primary structure, molecular weight, and branching, play a role in biological activities of β-l ,3-glucans. (Yadomae T., Structure and bioiogicai activities of fungal beta-l,3-glucans. Yakugaku Zasshi. 2000;120:413-431.) [0075] β-1,3-9ΐυοαη$ are naturally occurring polysaccharides, with or without β-l ,6giucose side chains that are found in the ceil walls of a variety of plants, yeasts, fungi and bacteria, β-l ,3;1,6-glucans are those containing glucose units with (1,3) links having side chains attached at the (1,6) position(s). β-l ,3;1,6 glucans are a heterogeneous group of glucose polymers that share structural commonaiities, including a backbone of straight chain glucose units linked by a β-l ,3 bond with β-l ,6linked giucose branches extending from this backbone. While this is the basic structure
WO 2017/083067
PCT/US2016/057641 for the presently described class of β-giucans, some variations may exist. For example, certain yeast β-giucans have additional regions of β{1,3) branching extending from the β(1,6) branches, which add further complexity to their respective structures.
[0076] β-glucans derived from baker's yeast, Saccharomyces cerevisiae, are made up of chains of D-glucose molecules connected at the 1 and 3 positions, having side chains of glucose attached at the 1 and 6 positions. Yeast-derived β-glucan is an insoluble, fiber-iike, complex sugar having the general structure of a linear chain of glucose units with a β-1,3 backbone interspersed with β-l ,6 side chains that are generally 6-8 glucose units in iength. More specifically, β-glucan derived from baker’s yeast is poly-(l ,6)^-D-glucopyranosyl-(l ,3}^-D-glucopyranose.
[0077] Furthermore, β-glucans are well tolerated and do not produce or cause excess gas, abdominal distension, bloating or diarrhea in pediatric subjects. Addition of βglucan to a nutritional composition for a pediatric subject, such as an infant formula, a growing-up milk or another children's nutritional product, wiii improve the subject’s immune response by increasing resistance against invading pathogens and therefore maintaining or improving overall health.
[0078] In some embodiments, the β-glucan is β-l ,3;1,6-glucan. In some embodiments, the β-l ,3;1,6-glucan is derived from baker's yeast. The nutritional composition may comprise whole glucan particle β-glucan, particulate β-glucan, PGG-glucan (poly-1,6β-D-glucopyranosyl-l ,3-p-D-g!ucopyranose) or any mixture thereof.
[0079] In some embodiments, the amount of β-glucan in the nutritionai composition is between about 3 mg and about 17 mg per 100 Kcai. In another embodiment the amount of β-giucan is between about 6 mg and about 17 mg per 100 Kcal.
[0080] The disclosed nutritionai composition described herein can, in some embodiments, also comprise a source of probiotic. The term “probiotic means a microorganism that exerts beneficial effects on the health of the host. Any probiotic known in the art may be acceptable in this embodiment, in a particular embodiment, the probiotic may be selected from any Lactobaciiius species, Lactobacilius rhamnosus GG (ATCC number 53103), Bifidobacterium species, Bifidobacterium longum BB536 (BL999, ATCC: BAA-999), Bifidobacterium longum AHI 206 (NC1MB: 41382), Bifidobacterium breve AH 1205 (NCIMB: 41387), Bifidobacterium infantis 35624 (NCIMB: 41003), and Bifidobacterium animalis subsp. lactis BB-12 (DSM No. 10140) or any combination thereof.
WO 2017/083067
PCT/US2016/057641 [0081] If included, the nutritional composition may comprise between about 1 x 104 to about 1.5 x 10'° cfu of probiotics per 100 Kcal, more preferabiy from about 1 x 106 to about 1 x 109 cfu of probiotics per 100 Kcal.
[0082] In an embodiment, the probiotic(s) may be viable or non-viable. As used herein, the term “viable”, refers to live microorganisms. The term “non-viable” or “nonviable probiotic” means non-iiving probiotic microorganisms, their celiular components and/or metabolites thereof. Such non-viable probiotics may have been heat-kilied or otherwise inactivated, but they retain the ability to favorably influence the health of the host. The probiotics useful in the present disclosure may be naturally-occurring, synthetic or developed through the genetic manipulation of organisms, whether such new source is now known or later developed.
[0083] The disclosed nutritional composition described herein can, in some embodiments, also comprise a source of prebiotics. The term “prebiotic” as used herein refers to indigestible food ingredients which exert health benefits upon the host. Such health benefits may include, but are not limited to, selective stimulation of the growth and/or activity of one or a limited number of beneficial gut bacteria, stimulation of the growth and/or activity of ingested probiotic microorganisms, selective reduction in gut pathogens, and favorable influence on gut short chain fatty acid profile. Such prebiotics may be naturally-occurring, synthetic, or developed through the genetic manipulation of organisms and/or plants, whether such new source is now known or developed later. Prebiotics useful in the present disclosure may include oligosaccharides, polysaccharides, and other prebiotics that contain fructose, xylose, soya, galactose, glucose and mannose.
[0084] More specifically, prebiotics useful in the present disclosure may include polydextrose, polydextrose powder, lactuiose, iactosucrose, raffinose, giucooiigosaccharide, inuiin, fructo-oligosaccharide, isomaito-oligosaccharide, soybean oligosaccharides, Iactosucrose, xylo-oligosaccharide, chito-oligosaccharide, mannooligosaccharide, aribino-oligosaccharide, siailyl-oligosaccharide, fucooligosaccharide, galacto-oligosaccharide, and gentio-oligosaccharides. In one preferred embodiment, the prebiotic comprises galacto-oligosaccharide, polydextrose, or mixtures thereof.
[0085] The amount of galacto-oiigosaccharide in the nutritionai composition may, in an embodiment, be from about 0.1 g/100 Kcal to about 1.5 g/100 Kcai. In another embodiment, the amount of gaiacto-oiigosaccharide in the nutritionai composition may be from about 0.1 g/100 Kcal to about 1.0 g/100 Kcal. The amount of
WO 2017/083067
PCT/US2016/057641 polydextrose in the nutritiona! composition may, in an embodiment, be within the range of from about 0.1 g/100 Kcal to about 1.5 g/100 Kcai. In a particular embodiment, galacto-oligosaccharide and polydextrose are supplemented into the nutritional composition in a total amount of about at least about 0.2 g/100 Kcal and can be about 0.2 g/100 Kcal to about 1.5 g/100 Kcal. In some embodiments, the nutritional composition may comprise galactooligosaccharide and poiydextrose in a total amount of from about 0.6 to about .8 g/100 Kcal.
[0086] The disclosed nutritiona! composition described herein, can, in some embodiments also comprise an effective amount of iron. The iron may comprise encapsulated iron forms, such as encapsulated ferrous fumarate or encapsulated ferrous sulfate or less reactive iron forms, such as ferric pyrophosphate or ferric orthophosphate.
[0087] One or more vitamins and/or minerals may also be added in to the nutritional composition in amounts sufficient to supply the daily nutritional requirements of a subject. It is to be understood by one of ordinary skil! in the art that vitamin and mineral requirements wiii vary, for example, based on the age of the child. For instance, an infant may have different vitamin and mineral requirements than a child between the ages of one and thirteen years. Thus, the embodiments are not intended to limit the nutritional composition to a particular age group but, rather, to provide a range of acceptabie vitamin and mineral components.
[0088] In embodiments providing a nutritional composition for a child, the composition may optionally include, but is not limited to, one or more of the following vitamins or derivations thereof: vitamin Bi (thiamin, thiamin pyrophosphate, TPP, thiamin triphosphate, TTP, thiamin hydrochloride, thiamin mononitrate), vitamin B2 (riboflavin, flavin mononucleotide, FMN, flavin adenine dinucieotide, FAD, iactoflavin, ovoflavin), vitamin B3 (niacin, nicotinic acid, nicotinamide, niacinamide, nicotinamide adenine dinucleotide, NAD, nicotinic acid mononucleotide, NicMN, pyridine-3-carboxyiic acid), vitamin B3-precursor tryptophan, vitamin Bi (pyridoxine, pyridoxai, pyridoxamine, pyridoxine hydrochloride), pantothenic acid (pantothenate, panthenoi), foiate (foiic acid, foiacin, pteroylglutamic acid), vitamin B12 (cobaiamin, methyicobaiamin, deoxyadenosyicobaiamin, cyanocobaiamin, hydroxycobalamin, adenosyicobaiamin), biotin, vitamin C (ascorbic acid), vitamin A (retinol, retinyi acetate, retinyl palmitate, retinyl esters with other long-chain fatty acids, retinal, retinoic acid, retinol esters), vitamin D (caiciferol, cholecalciferol, vitamin Ds, 1,25,-dihydroxyvitamin D), vitamin E (atocopheroi, a-tocopherol acetate, a-tocopherol succinate, a-tocopheroi nicotinate,
WO 2017/083067
PCT/US2016/057641 α-tocopherol), vitamin K (vitamin Ki, phyiioquinone, naphthoquinone, vitamin K2, menaquinone-7, vitamin K3, menaquinone-4, menadione, menaquinone-8, menaquinone-8H, menaquinone-9, menaquinone-9H, menaquinone-10, menaquinone-11, menaquinone-12, menaquinone-13), choiine, inositoi, β-carotene and any combinations thereof.
[0089] in embodiments providing a chiidren's nutritional product, such as a growing-up milk, the composition may optionally include, but is not limited to, one or more of the foliowing minerals or derivations thereof: boron, calcium, calcium acetate, calcium gluconate, calcium chloride, calcium lactate, calcium phosphate, caicium sulfate, chloride, chromium, chromium chloride, chromium picolonate, copper, copper sulfate, copper giuconate, cupric sulfate, fluoride, iron, carbonyl iron, ferric iron, ferrous fumarate, ferric orthophosphate, iron trituration, polysaccharide iron, iodide, iodine, magnesium, magnesium carbonate, magnesium hydroxide, magnesium oxide, magnesium stearate, magnesium sulfate, manganese, molybdenum, phosphorus, potassium, potassium phosphate, potassium iodide, potassium chloride, potassium acetate, selenium, sulfur, sodium, docusate sodium, sodium chloride, sodium seienate, sodium molybdate, zinc, zinc oxide, zinc suifate and mixtures thereof. Non-limiting exemplary derivatives of mineral compounds include salts, alkaline salts, esters and cheiates of any mineral compound.
[0090] The minerals can be added to growing-up milks or to other children's nutritional compositions in the form of salts such as caicium phosphate, caicium glycerol phosphate, sodium citrate, potassium chloride, potassium phosphate, magnesium phosphate, ferrous suifate, zinc sulfate, cupric sulfate, manganese suifate, and sodium selenite. Additional vitamins and minerals can be added as known within the art.
[0091] The nutritional compositions of the present disciosure may optionally include one or more of the following flavoring agents, including, but not limited to, flavored extracts, volatile oils, cocoa or chocolate flavorings, peanut butter flavoring, cookie crumbs, vanilla or any commercialiy available flavoring. Examples of useful flavorings include, but are not limited to, pure anise extract, imitation banana extract, imitation cherry extract, chocolate extract, pure iemon extract, pure orange extract, pure peppermint extract, honey, imitation pineapple extract, imitation rum extract, imitation strawberry extract, or vanilla extract; or volatile oils, such as balm oil, bay oil, bergamot oil, cedarwood oil, cherry oil, cinnamon oii, ciove oil, or peppermint oii; peanut butter, chocolate flavoring, vanilla cookie crumb, butterscotch, toffee, and mixtures thereof. The amounts of flavoring agent can vary greatly depending upon the flavoring agent
WO 2017/083067
PCT/US2016/057641 used. The type and amount of flavoring agent can be selected as is known in the art. [0092] The nutritional compositions of the present disclosure may optionally include one or more emulsifiers that may be added for stability of the final product. Examples of suitable emulsifiers include, but are not limited to, lecithin (e.g., from egg or soy), alpha lactalbumin and/or mono- and di-giycerides, and mixtures thereof. Other emulsifiers are readily apparent to the skilled artisan and selection of suitable emulsifier(s) will depend, in part, upon the formulation and final product.
[0093] The nutritional compositions of the present disclosure may optionally include one or more preservatives that may also be added to extend product shelf life. Suitable preservatives include, but are not limited to, potassium sorbate, sodium sorbate, potassium benzoate, sodium benzoate, calcium disodium EDTA, and mixtures thereof. [0094] The nutritional compositions of the present disclosure may optionally include one or more stabilizers. Suitable stabilizers for use in practicing the nutritional composition of the present disclosure include, but are not limited to, gum arabic, gum ghatti, gum karaya, gum tragacanth, agar, furcellaran, guar gum, gellan gum, locust bean gum, pectin, low methoxyl pectin, gelatin, microcrystalline cellulose, CMC (sodium carboxymethylcelluiose), methylcellulose hydroxypropyl methyl cellulose, hydroxypropyl cellulose, DATEM (diacetyl tartaric acid esters of mono- and diglycerides), dextran, carrageenans, and mixtures thereof.
[0095] The nutritionai compositions of the disclosure may provide minimal, partial or total nutritional support. The compositions may be nutritional supplements or meal replacements. The compositions may, but need not, be nutritionally complete. In an embodiment, the nutritional composition of the disclosure is nutritionally complete and contains suitable types and amounts of lipid, carbohydrate, protein, vitamins and minerals. The amount of lipid or fat typically can vary from about 1 to about 25 g/100 Kcal. The amount of protein typically can vary from about 1 to about 7 g/100 Kcal. The amount of carbohydrate typically can vary from about 6 to about 22 g/100 Kcal.
[0096] In an embodiment, the children's nutritional composition may contain between about 10 and about 50% of the maximum dietary recommendation for any given country, or between about 10 and about 50% of the average dietary recommendation for a group of countries, per serving of vitamins A, C, and E, zinc, iron, iodine, selenium, and choiine. In another embodiment, the children’s nutritional composition may supply about 10 - 30% of the maximum dietary recommendation for any given country, or about 10 - 30% of the average dietary recommendation for a group of countries, per serving of B-vitamins. In yet another embodiment, the levels of vitamin D, calcium,
WO 2017/083067
PCT/US2016/057641 magnesium, phosphorus, and potassium in the children's nutritional product may correspond with the average levels found in milk, in other embodiments, other nutrients in the children’s nutritional composition may be present at about 20% of the maximum dietary recommendation for any given country, or about 20% of the average dietary recommendation for a group of countries, per serving.
[0097] In some embodiments the nutritional composition is an infant formula. Infant formulas are fortified nutritional compositions for an infant. The content of an infant formula is dictated by federal regulations, which define macronutrient, vitamin, mineral, and other ingredient levels in an effort to simulate the nutritional and other properties of human breast milk. Infant formulas are designed to support overall health and development in a pediatric human subject, such as an infant or a child. [0098] In some embodiments, the nutritional composition of the present disclosure is a growing-up milk. Growing-up milks are fortified milk-based beverages intended for children over 1 year of age (typicaiiy from 1-3 years of age, from 4-6 years of age or from 1-6 years of age). They are not medical foods and are not intended as a meal repiacement or a supplement to address a particular nutritional deficiency. Instead, growing-up milks are designed with the intent to serve as a complement to a diverse diet to provide additional insurance that a child achieves continual, daily intake of all essential vitamins and minerals, macronutrients plus additional functional dietary components, such as non-essentiai nutrients that have purported health-promoting properties.
[0099] The exact composition of a growing-up miik or other nutritionai composition according to the present disciosure can vary from market-to-market, depending on local regulations and dietary intake information of the population of interest. In some embodiments, nutritionai compositions according to the disclosure consist of a milk protein source, such as whoie or skim milk, plus added sugar and sweeteners to achieve desired sensory properties, and added vitamins and minerals. The fat composition includes an enriched lipid fraction derived from milk. Totai protein can be targeted to match that of human milk, cow milk or a lower value. Total carbohydrate is usually targeted to provide as little added sugar, such as sucrose or fructose, as possible to achieve an acceptable taste. Typicaliy, Vitamin A, calcium and Vitamin D are added at levels to match the nutrient contribution of regional cow milk. Otherwise, in some embodiments, vitamins and minerals can be added at levels that provide approximately 20% of the dietary reference intake (DRI) or 20% of the Daily Value (DV) per serving. Moreover, nutrient values can vary between markets depending on the
WO 2017/083067
PCT/US2016/057641 identified nutritional needs of the intended population, raw material contributions and regional regulations.
[0100] The disclosed nutritionai composition(s) may be provided in any form known in the art, such as a powder, a gei, a suspension, a paste, a solid, a liquid, a liquid concentrate, a reconstituteable powdered milk substitute or a ready-to-use product. The nutritionai composition may, in certain embodiments, comprise a nutritionai supplement, children's nutritionai product, infant formula, human milk fortifier, growingup milk or any other nutritional composition designed for an infant or a pediatric subject. Nutritional compositions of the present disclosure include, for example, orallyingestible, health-promoting substances including, for example, foods, beverages, tablets, capsules and powders. Moreover, the nutritionai composition of the present disclosure may be standardized to a specific caloric content, it may be provided as a ready-to-use product, or it may be provided in a concentrated form. In some embodiments, the nutritional composition is in powder form with a particle size in the range of 5 pm to 1500 pm, more preferably in the range of 10 pm to 300pm.
[0101] In certain embodiments, the disclosure is directed to a method of producing a nutritional composition comprising dietary butyrate that has improved organoleptic properties. For example, in certain embodiments, the nutritional composition includes dietary butyrate that has been encapsulated or coated according to the disclosure provided herein.
[0102] Ail combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or ciearly implied to the contrary by the context in which the referenced combination is made.
[0103] The methods and compositions of the present disclosure, including components thereof, can comprise, consist of, or consist essentially of the essential elements and limitations of the embodiments described herein, as well as any additional or optional ingredients, components or limitations described herein or otherwise useful in nutritionai compositions.
[0104] Formulation examples are provided to illustrate some embodiments of the nutritional composition of the present disclosure but should not be interpreted as any limitation thereon. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from the consideration of the specification or practice of the nutritional composition or methods disclosed herein. It is intended that the specification, together with the example, be considered to be exemplary only, with the
WO 2017/083067
PCT/US2016/057641 scope and spirit of the disclosure being indicated by the claims which follow the example.
FORMULATION EXAMPLES
Table 1 [0105] Table 1, illustrated below, provides an example embodiment of the nutritional profile of a nutritional composition including dietary butyrate and describes the amount of each ingredient to be included per 100 Kcal serving of nutritional composition.
Table 1. Nutrition profile of an example nutritional composition including dietary butyrate
per 100 Kcal
Nutrienf/Lipid
Minimum Maximum
Protein (g) 1.2 6.8
Fat total including enriched lipid fraction (g) 1.4 10.3
Carbohydrates (g) 6 22
Prebiotic (g) 0.3 1.2
DHA (mg) 4 32
Beta glucan (mg) 2.9 17
Saturated Fatty acids (g) 0.1 2.3
Trans-fatty acid (g) 0.1 1.2
OBCFAs (g) 0.05 1.0
CLA (g) 0.05 1.0
Cholesterol (mg) 100 400
Milk Phospholipids (mg) 50 500
Phosphotidyichoiine (mg) 130 400
SphingoMyeiin (mg) 5 60
BCFAs (g) 0.3 2.3
Probiotics (cfu) 9.60 x 10s 3.80 χ 108
Vitamin A (IU) 134 921
Vitamin D (IU) 22 126
Vitamin E (IU) 0.8 5.4
WO 2017/083067
PCT/US2016/057641
Vitamin K (meg) 2.9 18
Thiamin (meg) 63 328
Riboflavin (meg) 68 420
Vitamin B6 (meg) 52 397
Vitamin BI2 (meg) 0.2 0.9
Niacin (meg) 690 5881
Foiic acid (meg) 8 66
Panthothenic acid (meg) 232 1211
Biotin (meg) 1.4 5.5
Vitamin C (mg) 4.9 24
Choline (mg) 4.9 43
Caicium (mg) 68 297
Phosphorus (mg) 54 210
Magnesium (mg) 4.9 34
Sodium (mg) 24 88
Potassium (mg) 82 346
Chloride (mg) 53 237
Iodine (meg) 8.9 79
Iron (mg) 0.7 2.8
Zinc (mg) 0.7 2.4
Manganese (meg) 7.2 41
Copper (meg) 16 331
[01061 Ail references cited in this specification, including without limitation, all papers, publications, patents, patent applications, presentations, texts, reports, manuscripts, brochures, books, internet postings, journal articles, periodicals, and the like, are hereby incorporated by reference into this specification in their entireties. The discussion of the references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinence of the cited references.
[0107] Although embodiments of the disclosure have been described using specific terms, devices, and methods, such description is for illustrative purposes only. The words used are words of description rather than of limitation. It is to be understood that changes and variations may be made by those of ordinary skill in the art without departing from the spirit or the scope of the present disclosure, which is set forth in the
WO 2017/083067
PCT/US2016/057641 following claims, in addition, it should be understood that aspects of the various embodiments may be interchanged in whole or in part. Therefore, the spirit and scope of the appended claims should not be limited to the description of the versions contained therein.
WO 2017/083067
PCT/US2016/057641

Claims (20)

  1. What is claimed is:
    1. A nutritional composition comprising:
    a carbohydrate source; a protein source; a fat source;
    and dietary butyrate, wherein the dietary butyrate is selected from the group consisting of butyric acid; butyrate salts; glycerol esters of butyric acid; and combinations thereof.
  2. 2. The nutritional composition of claim 1, wherein the dietary butyrate is present in the nutritional composition in an amount of from about 0.2 g/100 g fatty acids to about 1.8 g/100 g fatty acids.
  3. 3. The nutritional composition of claim 2, wherein the dietary butyrate is encapsulated in a matrix composed of emulsifiers, such as mono-, di-, and organic esters of glycerides, carbohydrate hydrocolloids, such as natural, physical-, chemicalmodified starches, pectins, glucans, cyclodextrins, maltodextrins, and proteins, such as caseins, whey or soy derived to improve its organoleptic properties.
  4. 4. The nutritional composition of claim 2, wherein the dietary butyrate is coated with a matrix composed of emulsifiers, such as mono-, di-, and organic esters of glycerides, carbohydrate hydrocolioids, such as natural, physical-, chemical-modified starches, pectins, glucans, cyclodextrins, maltodextrins, and proteins, such as caseins, whey or soy derived to improve its organoleptic properties.
  5. 5. The nutritional composition of claim 1, wherein the dietary butyrate comprises glycerol esters of butyric acid.
  6. 6. The nutritional composition of claim 1, wherein the dietary butyrate comprises sodium butyrate, potassium butyrate, calcium butyrate, magnesium butyrate, or combinations thereof.
  7. 7. The nutritional composition of claim 1, wherein the dietary butyrate is formulated to be in complex form with chitosan or one or more cyclodextrins.
  8. 8. The nutritional composition of claim 1, further comprising one or more long chain polyunsaturated fatty acids.
  9. 9. The nutritional composition of claim 8, wherein the one or more long chain polyunsaturated fatty acids comprises one of the following selected from the group consisting of docosahexaenoic acid, arachidonic acid, and combinations thereof.
    WO 2017/083067
    PCT/US2016/057641
  10. 10. The nutritional composition of claim 8, wherein the long chain polyunsaturated fatty acids are present in an amount of from about 5 mg/100 Kcal to about 100 mg/100
    Kcal.
  11. 11. The nutritional composition of claim 1, further comprising one or more probiotics.
  12. 12. The nutritional composition of claim 11, wherein the probiotic comprises
    LactobaciHus rhamnosus GG.
  13. 13. The nutritional composition of claim 1, further comprising one or more prebiotics.
  14. 14. The nutritional composition of claim 13, wherein the prebiotics comprise polydextrose and galactooligosaccharides.
  15. 15. The nutritional composition of claim 1, further comprising β-glucan.
  16. 16. The nutritional composition of claim 1, wherein the nutritionai composition is an infant formula.
  17. 17. A nutritional composition comprising a fat source and dietary butyrate, wherein the dietary butyrate is selected from the group consisting of butyric acid; butyrate salts; glycerol esters of butyric acid; and combinations thereof.
  18. 18. The nutritionai composition of claim 17, wherein the nutritional composition further comprises a prebiotic.
  19. 19. The nutritionai composition of claim 17, wherein the nutritional composition further comprises a probiotic.
  20. 20. The nutritionai composition of claim 17, wherein the nutritional composition further comprises long chain polyunsaturated fatty acids.
AU2016351454A 2015-11-09 2016-10-19 Nutritional compositions containing butyrate and uses thereof Abandoned AU2016351454A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14/936,014 2015-11-09
US14/936,014 US20170127693A1 (en) 2015-11-09 2015-11-09 Nutritional compositions containing butyrate and uses thereof
US14/959,107 US10034937B2 (en) 2015-12-04 2015-12-04 Synergistic nutritional compositions and uses thereof
US14/959,107 2015-12-04
US15/011,797 2016-02-01
US15/011,797 US20170215464A1 (en) 2016-02-01 2016-02-01 Nutritional compositions containing dietary butyrate and uses thereof
PCT/US2016/057641 WO2017083067A1 (en) 2015-11-09 2016-10-19 Nutritional compositions containing butyrate and uses thereof

Publications (1)

Publication Number Publication Date
AU2016351454A1 true AU2016351454A1 (en) 2018-05-10

Family

ID=57227128

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2016351455A Active AU2016351455B2 (en) 2015-11-09 2016-10-19 Nutritional compositions comprising Lactobacillus rhamnosus GG, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate
AU2016351454A Abandoned AU2016351454A1 (en) 2015-11-09 2016-10-19 Nutritional compositions containing butyrate and uses thereof
AU2016351456A Active AU2016351456B2 (en) 2015-11-09 2016-10-19 Nutritional compositions comprising a casein hydrolysate, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate
AU2020257046A Active AU2020257046B2 (en) 2015-11-09 2020-10-20 Nutritional compositions comprising a casein hydrolysate, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2016351455A Active AU2016351455B2 (en) 2015-11-09 2016-10-19 Nutritional compositions comprising Lactobacillus rhamnosus GG, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2016351456A Active AU2016351456B2 (en) 2015-11-09 2016-10-19 Nutritional compositions comprising a casein hydrolysate, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate
AU2020257046A Active AU2020257046B2 (en) 2015-11-09 2020-10-20 Nutritional compositions comprising a casein hydrolysate, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate

Country Status (12)

Country Link
EP (3) EP3373748A1 (en)
JP (3) JP2018537441A (en)
CN (3) CN108347984A (en)
AU (4) AU2016351455B2 (en)
BR (3) BR112018008726A2 (en)
CA (3) CA3004722A1 (en)
HK (1) HK1256282A1 (en)
MX (3) MX2018005651A (en)
PH (3) PH12018500994A1 (en)
SG (3) SG11201803123PA (en)
TW (3) TW201729693A (en)
WO (3) WO2017083067A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140308212A1 (en) 2011-11-07 2014-10-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
US20210085744A1 (en) * 2017-11-22 2021-03-25 University Of Louisville Research Foundation, Inc. Edible plant-derived nanoparticles for regulation of gut microbiota
IT201800003557A1 (en) * 2018-03-14 2019-09-14 Kolfarma S R L Pharmaceutical preparation or food supplement based on alpha-lactalbumin
WO2020127642A1 (en) * 2018-12-21 2020-06-25 Société des Produits Nestlé S.A. Dietary butyrate for treating or preventing an allergic disorder
EP4068989A1 (en) * 2019-12-05 2022-10-12 Société des Produits Nestlé S.A. Dietary butyrate
CN116585284B (en) * 2023-06-13 2024-03-19 常州市武进人民医院(常州市第八人民医院) Calcitriol soft capsule, preparation method and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
AU2004318688A1 (en) * 2004-03-23 2005-11-03 Lytone Enterprise, Inc. Chitosan embedded or encapsulated capsule
RU2428056C2 (en) * 2005-04-27 2011-09-10 Н.В. Нютрисиа Alimentation containing lipids and indigestible saccharides
JP2007131550A (en) * 2005-11-08 2007-05-31 Snow Brand Milk Prod Co Ltd Immunity function regulator
ITRM20080214A1 (en) * 2008-04-21 2009-10-22 Uni Degli Studi Di Napoli Federico Ii DERIVATIVES OF BUTIRRIC ACID ADMINISTRATIVE BY ORAL, FORMULATIONS THAT CONTAIN THEM AND THEIR CLINICAL USE.
IT1392214B1 (en) * 2008-11-28 2012-02-22 Sila S R L PROCESS FOR THE PRODUCTION OF A COMPOUND OF N-BUTIRRIC ACID IN MICROCAPSULATED FORM, INTENDED FOR ANIMAL OR HUMAN POWER
IT1395328B1 (en) * 2009-08-26 2012-09-14 Alpiflor S R L COMPOSITION OF BUTIRRIC ACID MIXED WITH PROBIOTICS AND PREBIOTICS
CN103238730B (en) * 2012-03-22 2014-09-03 杭州康德权饲料有限公司 Preparation method of microencapsulation diolame sodium butyrate
WO2013191533A1 (en) * 2012-06-18 2013-12-27 N.V. Nutricia Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat
US9352020B2 (en) * 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US8889633B2 (en) * 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US10709770B2 (en) * 2013-07-31 2020-07-14 Mead Johnson Nutrition Company Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US20150119322A1 (en) * 2013-07-31 2015-04-30 Mead Johnson Nutrition Company Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US20150271554A1 (en) * 2014-03-18 2015-09-24 Telefonaktiebolaget L M Ericsson (Publ) Unified rating system and method for selectively blocking content
US20150305384A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics

Also Published As

Publication number Publication date
HK1256282A1 (en) 2019-09-20
TW201729691A (en) 2017-09-01
CN108347985A (en) 2018-07-31
AU2016351455A1 (en) 2018-05-10
CN108347984A (en) 2018-07-31
WO2017083068A1 (en) 2017-05-18
MX2018005663A (en) 2018-08-01
AU2020257046A1 (en) 2020-11-12
CA3004737A1 (en) 2017-05-18
AU2016351456B2 (en) 2020-09-17
AU2020257046B2 (en) 2022-08-11
MX2018005659A (en) 2018-08-01
BR112018008040A2 (en) 2018-11-13
PH12018500992A1 (en) 2018-11-12
CA3004740A1 (en) 2017-05-18
MX2018005651A (en) 2018-08-01
CA3004722A1 (en) 2017-05-18
EP3373748A1 (en) 2018-09-19
AU2016351455B2 (en) 2020-08-20
EP3373749A1 (en) 2018-09-19
AU2016351456A1 (en) 2018-05-10
PH12018500993A1 (en) 2018-11-12
BR112018008833A2 (en) 2018-11-06
SG11201803123PA (en) 2018-05-30
TW201729693A (en) 2017-09-01
WO2017083067A1 (en) 2017-05-18
SG11201803121WA (en) 2018-05-30
EP3373747A1 (en) 2018-09-19
CN108347986A (en) 2018-07-31
BR112018008833A8 (en) 2019-02-26
JP2018537084A (en) 2018-12-20
BR112018008726A2 (en) 2018-10-30
TW201729692A (en) 2017-09-01
PH12018500994A1 (en) 2019-01-28
JP2018537441A (en) 2018-12-20
SG11201803125XA (en) 2018-05-30
JP2018532417A (en) 2018-11-08
WO2017083069A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
AU2014219364B2 (en) Amino acid and protein hydrolysate based formulas with a stable emulsion system
AU2020257046B2 (en) Nutritional compositions comprising a casein hydrolysate, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate
US20170127693A1 (en) Nutritional compositions containing butyrate and uses thereof
AU2015324390B2 (en) Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile
WO2015084532A1 (en) Probiotic stabilization
WO2015088706A1 (en) Nutritional compositions containing stearidonic acid and uses thereof
AU2014357610B2 (en) Probiotic stabilization
CA2879393C (en) Nutritional creamer composition
US10034937B2 (en) Synergistic nutritional compositions and uses thereof
US20170215464A1 (en) Nutritional compositions containing dietary butyrate and uses thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted